Weakness in the ICU: Guillain-Barré syndrome, myasthenia gravis, critical illness polyneuropathy/myopathy

Neurologist

Volumn 11, Issue 6, 2005, Pages 338-347

  Green, Deborah M ^a,b  

^a UNIVERSITY OF HAWAII   (United States)

^b Stroke Center   (United States)

Author keywords

Critical illness myopathy; Critical illness polyneuropathy; Guillain Barr syndrome; ICU weakness; Myasthenia gravis

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA INTERFERON; CHLOROQUINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN; ERYTHROMYCIN; HEPARIN; IMMUNOGLOBULIN; INSULIN; LITHIUM; LOW MOLECULAR WEIGHT HEPARIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NERVE GROWTH FACTOR; NEUROMUSCULAR BLOCKING AGENT; PENICILLAMINE; PHENYTOIN; PREDNISONE; PROCAINAMIDE; PYRIDOSTIGMINE; VERAPAMIL;

ARTICLE; CLINICAL TRIAL; CRITICAL ILLNESS; DECUBITUS; DISEASE SEVERITY; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INSULIN TREATMENT; INTENSIVE CARE UNIT; INTUBATION; LUNG FUNCTION; MORBIDITY; MORTALITY; MYASTHENIA GRAVIS; MYOPATHY; PATHOGENESIS; PHYSIOTHERAPY; PLASMAPHERESIS; POLYNEUROPATHY; PRIORITY JOURNAL; RECURRENCE RISK; SPIROMETRY; STOMACH ULCER; THYMECTOMY; TRACHEOSTOMY; TREATMENT OUTCOME; VEIN THROMBOSIS;

GUILLAIN-BARRE SYNDROME; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INTENSIVE CARE UNITS; INTUBATION, INTRATRACHEAL; MUSCLE WEAKNESS; MUSCULAR DISEASES; MYASTHENIA GRAVIS; PLASMA EXCHANGE; POLYNEUROPATHIES; PROGNOSIS; TREATMENT OUTCOME;

EID: 27944487888     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.nrl.0000163784.17602.57     Document Type: Article

References (62)

1. Ad Hoc NINCDS Committee. Criteria for the diagnosis of Guillain-Barré syndrome. Ann Neurol 1978;3:565-566.
2. Loh L. Neurological and neuromuscular disease. Br J Anaesth. 1986;58:190-200.
3. Ropper AH, Gress DR, Diringer MN, et al. Critical care of Guillain-Barré syndrome. In: Neurological and Neurosurgical Intensive Care. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2004:278-298.
4. Ropper AH, Kehne SM. Guillain-Barré syndrome: management of respiratory failure. Neurology. 1985;35:1662-1665.
5. Newton-John H. Prevention of pulmonary complications in severe Guillain-Barré syndrome by early assisted ventilation. Med J Aust. 1985;142:444-445.
6. Chevrolet JC, Deléamont P. Repeated vital capacity measurements as predictive parameters for mechanical ventilation need and weaning success in the Guillain-Barré syndrome. Am Rev Respir Dis. 1991;144:814-818.
7. Lawn ND, Fletcher DD, Henderson RD, et al. Anticipating mechanical ventilation in Guillain-Barré syndrome. Arch Neurol. 2001;58:893-898.
8. Green DM. Advances in the management of Guillain-Barré syndrome. Curr Neurol Neurosci Rep. 2002;2:541-548.
9. Gaber TA, Kirker SG, Jenner JR. Current practice of prophylactic anticoagulation in Guillain-Barré syndrome. Clin Rehabil. 2002;16:190-193.
10. Hund EF, Borel CO, et al. Intensive management and treatment of severe Guillain-Barré syndrome. Crit Care Med. 1993;21:433-446.
11. Tripathi M, Kaushik S. Carbamazepine for pain management in Guillain-Barré syndrome patients in the intensive care unit. Crit Care Med. 2000;28:655-658.
12. Borel CO, Teitelbaum JS, Hanley DF. Ventilatory drive and carbon dioxide response in ventilatory failure due to myasthenia gravis and Guillain-Barré syndrome. Crit Care Med. 1993;21:1717-1726.
13. Montgomery AB, Holle RH, Neagley SR, et al. Prediction of successful ventilator weaning using airway occlusion pressure and hypercapnic challenge. Chest. 1987;91:496-499.
14. Borel CO, Tilford C, Nichols DG, et al. Diaphragmatic performance during recovery from acute ventilatory failure in Guillain-Barré syndrome and myasthenia gravis. Chest. 1991;99:444-451.
15. The Guillain-Barré Syndrome Study Group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology. 1985;35:1096-1104.
16. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann Neurol. 1987;22:753-761.
17. Dutch Guillain-Barré Study Group, van der Meché FGA, Shmitz PIM. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. New Engl J Med. 1992;326:1123-1129.
18. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet. 1997;349:225-230.
19. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Appropriate number of plasma exchanges in Guillain-Barré syndrome. Ann Neurol. 1997;41:298-306.
20. Weinstein RW. Therapeutic apheresis in neurological disorders. J Clin Apheresis. 2000;15:74-128.
21. Ropper AH, Albers JW, Addison R. Limited relapse in Guillain-Barré syndrome after plasma exchange. Arch Neurol. 1988;45:314-315.
22. Castro LHM, Ropper AH. Human immune globulin infusion in Guillain-Barré syndrome: worsening during and after treatment. Neurology. 1993;43:1034-1036.
23. Kleyweg RP, van der Meché FGA, Meulstee J. Treatment of Guillain-Barré syndrome with high-dose gammaglobulin. Neurology. 1988;38:1639-1641.
24. Osterman PO, Fagius J, Säfwenberg, et al. Early relapse of acute inflammatory polyradiculoneuropathy after successful treatment with plasma exchange. Acta Neurol Scand. 1988;77:273-7.
25. Kleyweg RP, van der Meché FGA. Treatment related fluctuations in Guillain-Barré syndrome after high-dose immunoglobulins or plasma-exchange. J Neurol Neurosurg Psychiatry. 1991;54:957-960.
26. Jackson MC, Godwin-Austen RB, Whiteley AM. High-dose intravenous immunoglobulin in the treatment of Guillain-Barré syndrome: a preliminary open study. J Neurol. 1993;240:51-53.
27. Irani DN, Cornblath DR, Chaudry V, et al. Relapse in Guillain- Barré syndrome after treatment with human immune globulin. Neurology. 1993;43:872-875.
28. Green DM, Ropper AH. Mild Guillain-Barré syndrome. Arch Neurol. 2001;58:1098-1101.
29. Creange A, Chazaud B, Plonquet A, et al. IFN-α decreases adhesion and transmigration capacities of lymphocytes in Guillain-Barré syndrome. Neurology. 2001;57:1704-1706.
30. Wollinsky KH, Hülser PJ, Brinkmeier H, et al. CSF filtration is an effective treatment of Guillain-Barré syndrome: results of a randomized clinical trial. Neurology. 2001;57:774-779.
31. Haupt WF, Birkmann C, van der Ven C, et al. Apheresis and selective adsorption plus immunoglobulin treatment in Guillain-Barré syndrome. Ther Apher. 2000;4:198-200.
32. Diener H-C, Haupt WF, Kloss TM, et al. A preliminary, randomized, multicenter study comparing intravenous immunoglobulin, plasma exchange, and immune adsorption in Guillain-Barré syndrome. Eur Neurol. 2001;46:107-109.
33. Bensa S, Hadden RD, Hahn A, et al. Randomized controlled trial of brain-derived neurotrophic factor in Guillain-Barré syndrome: a pilot study. Eur J Neurol. 2000;7:423-426.
34. Vincent A, Palace J, Hilton-Jones D. Myasthenia gravis. J Neurol Neurosurg Psychiatry. 2001;357:2122-2128.
35. Wittbrodt ET. Drugs and myasthenia gravis: an update. Arch Intern Med. 1997;157:399-408.
36. Ropper AH, Gress DR, Diringer MN, et al. Treatment of the critically ill patient with myasthenia gravis. In: Neurological and Neurosurgical Intensive Care. 4th ed. Philadelphia: Lippincott, Williams & Wilkins; 2004:299-311.
37. Cohen MS, Younger D. Aspects of the natural history of myasthenia gravis: crisis and death. Ann N Y Acad Sci. 1981;377:670-677.
38. Fink ME. Treatment of the critically ill patient with myasthenia gravis. In: Ropper AH, ed. Neurological and Neurosurgical Intensive Care. 3rd ed. New York: Raven Press; 1993:351-362.
39. Rieder P, Louis M, Jolliet P, et al. The repeated measurement of vital capacity is a poor predictor of the need for mechanical ventilation in myasthenia gravis. Intensive Care Med. 1995;21:663-668.
40. Mayer S. Intensive care of the myasthenic patient. Neurology. 1997;48(Suppl 5):70S-75S.
41. Bedlack RS, Sanders DB. How to handle myasthenic crisis: essential steps in patient care. Postgrad Med J. 2000;107:211-222.
42. Thomas C, Mayer S, Gungor Y, et al. Myasthenic crisis: clinical features, mortality, complications and risk factors for prolonged intubation. Neurology. 1997;48:1253-1260.
43. Gajdos P, Chevret S, Bernard C, et al. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Ann Neurol. 1997;41:789-796.
44. Qureshi AI, Choudry MA, Akbar MS, et al. Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology. 1999;52:629.
45. Saperstein DS, Barohn RJ. Management of myasthenia gravis. Semin Neurol. 2004;24:41-48.
46. Wolfe GI, Kaminski HJ, Jaretski A II, et al. Development of a thymectomy trial in nonthymomatous myasthenia gravis patients receiving immunosuppressive therapy. Ann N Y Acad Sci. 2003;998:473-480.
47. Soleimani A, Moayyeri A, Akhondzadeh S, et al. Frequency of myasthenic crisis in relation to thymectomy in generalized myasthenia gravis: a 17-year experience. BMC Neurol. 2004;4:12.
48. Gronseth GS, Barohn RJ. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;55:7-15.
49. Watanabe A, Watanabe T, Obama T, et al. Prognostic factors for myasthenic crisis after transsternal thymectomy in patients with myasthenia gravis. J Thorac Cardiovasc Surg. 2004;127:868-876.
50. Bolton CF, Gilbert JJ, Hahn AF, et al. Polyneuropathy in critically ill patients. J Neurol Neurosurg Psychiatry. 1984;47:1223-1231.
51. Garnacho-Montero J, Madrazo-Osuna J, Garcia-Garmendia JL, et al. Critical illness polyneuropathy: risk factors and clinical consequences. A cohort study in septic patients. Intensive Care Med. 2001;27:1288-1296.
52. De Jonghe B, Sharshar T, Lefaucheur J-P, et al. Paresis acquired in the intensive care unit. A prospective multicenter study. JAMA. 2002;2859-2867.
53. DeJonghe B, Cook D, Sharshar T, et al. Acquired neuromuscular disorders in critically ill patients: a systematic review. Intensive Care Med. 1998;24:1242-1250.
54. Tepper M, Rakic S, Haas JA, et al. Incidence and onset of critical illness polyneuropathy in patients with septic shock. Neth J Med. 2000;56:211-214.
55. van Mook WNKA, Hulsewé-Evers RPMG. Critical illness polyneuropathy. Curr Opin Crit Care. 2002;8:302-310.
56. Hund E. Critical illness polyneuropathy. Curr Opin Neurol. 2001;14:649-653.
57. Griffiths RD, Palmer TE, Helliwell T, et al. Effect of passive stretching on the wasting muscle in the critically ill. Nutrition. 1995;11:428-432.
58. Van Den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001;345:1359-1367.
59. Van den Berghe G, Wouters PJ, Bouillon R, et al. Outcome benefit of intensive insulin therapy in the critically ill: insulin dose versus glycemic control. Crit Care Med. 2003;31:359-366.
60. De Jonghe B, Sharshar T, Hopkinson N, et al. Paresis following mechanical ventilation. Curr Opin Crit Care. 2004;10:47-52.
61. Mohr M, Englisch L, Roth A, et al. Effects of early treatment with immunoglobulin on critical illness polyneuropathy following multiple organ failure and Gram-negative sepsis. Intensive Care Med. 1997;23:1144-1149.
62. Wijdicks EF, Fulgham JR. Failure of high dose intravenous immunoglobulins to alter the clinical course of critical illness polyneuropathy. Muscle Nerve. 1994;17:1494-1495.